DJ VALBIOTIS SA: Valbiotis announces positive results from the Cardio-Liver clinical study - Commercial launch of ValbiotisPRO Foie on September 23
VALBIOTIS SA
VALBIOTIS SA: Valbiotis announces positive results from the Cardio-Liver clinical study - Commercial launch of
ValbiotisPRO Foie on September 23
22-Sep-2026 / 17:40 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=----------------------------------------------------------------------------------------------------------------------
Press Release
Valbiotis announces positive results from the Cardio-Liver
clinical study
Commercial launch of ValbiotisPRO Foie on September 23
-- The Cardio-Liver study demonstrates positive effects on various metabolic parameters and, in particular,
a reduction in liver fat content. It brings to a close the clinical development program of the active substance
Steadrive.
-- ValbiotisPRO Foie, based on the patented Steadrive formulation, will be marketed from September 23
across all channels in France: pharmacies and e-commerce.
-- The ValbiotisPRO range now comprises four solutions dedicated to managing the risk factors of
cardiometabolic imbalances, all based on clinically tested active substances.
La Rochelle, September 22, 2026 (5:40 PM CEST) - Valbiotis (FR0013254851 - ALVAL, PEA / PME eligible), a French
laboratory specializing in cardiometabolic health, announces the completion of the Cardio-Liver clinical study. The
results demonstrate the positive effects of Steadrive (formerly Totum.448) in a context of excess liver fat associated
with various metabolic disorders. These results enable the commercial launch of ValbiotisPRO Foie in France, from
September 23.
Cardio-Liver: positive results bringing the Steadrive clinical program to a close
Cardio-Liver is a randomized, placebo-controlled, double-blind clinical study conducted in 71 volunteers presenting
with hepatic steatosis (without significant associated fibrosis) and overweight or obesity. Participants were divided
into two arms and supplemented for 4 months with either Steadrive (4.28 g per day) or a placebo.
The results obtained confirm the positive effects of Steadrive on the accumulation of fat in the liver as well as on
various associated metabolic parameters. The Cardio-Liver study included a very large number of measurements, providing
additional information on the effects of Steadrive and its mechanisms of action in a context of hepatic steatosis.
This study reinforces the entire body of data accumulated on Steadrive, which has already been the subject of 4
publications in scientific journals and 14 communications at international congresses. Cardio-Liver, the detailed
results of which will be presented at an international scientific congress, thereby completes the clinical development
program of Steadrive.
The study was conducted in partnership with Université Laval in Quebec City, within the framework of a Research Chair
in "translational research on the mechanisms of action of plant-based compounds on metabolic hepatic steatosis", led by
Professor André Marette.
André Marette, principal investigator of the study, full professor at the Faculty of Medicine of Université Laval and
researcher at the Quebec Heart and Lung Institute (Institut universitaire de cardiologie et de pneumologie de Québec),
said: "We are very pleased to have the first results of this clinical study on Steadrive, which shows a reduction in
the accumulation of liver fat and will also help us better understand the mechanisms of action involved. Indeed, the
initial analyses highlight very promising results not only on the liver but also on the various metabolic parameters
measured in the subjects of this clinical study. We now look forward to sharing more detailed data with the scientific
community at an upcoming congress."
Pascal Sirvent, Medical and Scientific Director of Valbiotis, added: "The Cardio-Liver results reinforce the scientific
data already accumulated around Steadrive and confirm its value in the context of excess liver fat. They are
consistent with Valbiotis's commitment to rigorous clinical research and further strengthen the scientific foundation
underpinning the development of the ValbiotisPRO range, dedicated to cardiometabolic health."
ValbiotisPRO Foie: a natural, scientifically tested response to a major public health challenge
In France, nearly one adult in two is overweight with associated metabolic imbalances[1], and 20% of the population has
an excessive accumulation of fat in the liver[2]. These imbalances remain insufficiently identified, even though early,
appropriate prevention would help better preserve liver health.
This is precisely the challenge that ValbiotisPRO Foie addresses. Based on Steadrive, a patented plant-derived
formulation backed by more than 10 years of research, it acts directly on liver health and fat metabolism. It thus
provides support addressing various imbalances affecting liver function, ranging from digestive discomfort linked to an
over-rich diet or occasional excess through to the chronic accumulation of fat in the liver.
A launch across all channels from September 23
ValbiotisPRO Foie will be available from September 23 in pharmacies, in pillbox format, in pharmacies as well as on
the online store www.valbiotis.com.
Its launch will draw on the multichannel commercialization approach deployed for the ValbiotisPRO range: promotion to
pharmacists and partner pharmacy groups, training of pharmacy teams, point-of-sale and shelf display materials, and
targeted digital marketing campaigns.
A complete ValbiotisPRO range, backed by leading scientific credentials
Following ValbiotisPRO Cholestérol (May 2024), ValbiotisPRO Santé métabolique (February 2025) and ValbiotisPRO
Cardio-circulation (June 2025), the launch of ValbiotisPRO Foie completes, in line with the announced schedule, a
range of four solutions dedicated to maintaining cardiometabolic balance, each based on an active substance with
clinically demonstrated efficacy.
Backed by intellectual property covering more than 60 countries, this range benefits from an unrivalled clinical
foundation (13 studies in total) and leading scientific validation, with 69 selections at benchmark international
congresses and 17 scientific publications in international peer-reviewed journals.
The high point of this scientific recognition: the results of REVERSE-IT, a randomized study showing a significant
reduction in fasting blood glucose after 6 months with Totum.63 (ValbiotisPRO Santé métabolique), were published this
past July in Nature Communications, a journal renowned for its editorial and methodological rigor (press release of
July 22, 2026).
Shareholder Benefit
20 % discount on ValbiotisPRO and ValbiotisPLUS products, granted by customer service (service-client@valbiotis.com)
upon proof of holding at least 85 shares
Terms and Conditions: click here
About Valbiotis
Valbiotis is a French laboratory specializing in the development and distribution of scientifically tested first-line
nutritional solutions designed to prevent cardiometabolic imbalances. Through an innovative approach combining
scientific excellence, plant expertise and a wealth of natural ingredients, Valbiotis develops high -quality
formulations based on patented active ingredients validated by rigorous clinical studies, designed to provide long-term
support for cardiometabolic health and address associated functional issues such as sleep, fatigue, mood management,
immunity and vitality. Created at the beginning of 2014 in La Rochelle, France, Valbiotis has forged numerous
partnerships with leading academic centers. Valbiotis is a member of the "BPI Excellence" network and has been
recognized as an "Innovative Company" by the BPI label. Valbiotis has received major financial support from the
European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA PME
eligible company.
Contacts
Corporate Communication / Valbiotis
Caroline LAMBERTI
+ 33 6 77 82 56 88
caroline.lamberti@valbiotis.com
Financial communication / Seitosei.Actifin
Marianne PY
+33 6 85 52 76 93
marianne.py@seitosei-actifin.com
Press Relations / LJ Com by JIN
Valentine MARTIN
+33 6 32 29 43 82
v.martin@ljcom.net
Name: Valbiotis
ISIN code: FR0013254851
Ticker symbol: ALVAL
EnterNext© PEA-PME 150
This press release contains forward-looking statements regarding Valbiotis' objectives. Valbiotis considers that these
projections are based on information currently available to Valbiotis and on reasonable assumptions. However, they in
no way constitute guarantees of future performance and may be affected by changes in the economic environment,
financial markets and by a number of risks and uncertainties, available on the Company's website (www.valbiotis.com).
This press release and the information it contains do not constitute an offer to sell or subscribe, nor the
solicitation of an order to buy or subscribe for shares or financial securities of Valbiotis in any country.
=----------------------------------------------------------------------------------------------------------------------
[1] Ligue nationale contre l'Obésité - Observatoire Français d'Épidémiologie de l'Obésité (OFÉO), 2024 - overweight
(30.8%) + obesity (17.9%) combined.
(MORE TO FOLLOW) Dow Jones Newswires
September 22, 2026 11:40 ET (15:40 GMT)
© 2026 Dow Jones News
